Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
Clinical trial NCT02843659 · TERMINATED
Trial details
- NCT number
- NCT02843659
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-18
- Primary completion
- 2017-07-24
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.